- Home
- VIRT vs KNSA Comparison
VIRT vs KNSA Comparison
Compare VIRT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | VIRT | KNSA |
|---|---|---|
| Founded | 2008 | 2015 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.0B | 4.9B |
| IPO Year | 2014 | 2018 |
Fundamental Metrics
Financial Performance| Metric | VIRT | KNSA |
|---|---|---|
| Price | $57.76 | $77.19 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 7 |
| Target Price | $45.60 | ★ $60.86 |
| AVG Volume (30 Days) | ★ 1.2M | 415.4K |
| Earning Date | 04-29-2026 | 04-28-2026 |
| Dividend Yield | ★ 1.89% | N/A |
| EPS Growth | 72.73 | ★ 225.00 |
| EPS | ★ 3.62 | 0.27 |
| Revenue | ★ $3,632,118,000.00 | $677,564,000.00 |
| Revenue This Year | N/A | $37.48 |
| Revenue Next Year | $1.34 | $17.87 |
| P/E Ratio | ★ $15.82 | $293.81 |
| Revenue Growth | 26.25 | ★ 60.09 |
| 52 Week Low | $31.55 | $35.33 |
| 52 Week High | $68.76 | $82.94 |
Technical Indicators
Market Signals| Indicator | VIRT | KNSA |
|---|---|---|
| Relative Strength Index (RSI) | 39.48 | 54.16 |
| Support Level | $56.81 | $44.95 |
| Resistance Level | $60.97 | $81.97 |
| Average True Range (ATR) | 2.01 | 2.39 |
| MACD | -0.94 | -0.39 |
| Stochastic Oscillator | 12.70 | 56.80 |
Price Performance
Historical ComparisonAbout VIRT Virtu Financial Inc.
Virtu Financial Inc is a financial firm that leverages technology to deliver liquidity to the world-wide markets and transparent trading solutions to its clients. The company's operating segment includes Market Making; and Execution Services. The non-operating segment of the company includes the Corporate segment. The company generates maximum revenue from the market-making segment. The Market Making segment principally consists of market-making in the cash, futures, and options markets across equities, options, fixed income, currencies, and commodities. Geographically, it derives a majority of its revenue from the United States and also has a presence in Ireland and Other Countries.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating cardiovascular diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and Vixarelimab. Geographically, the company earns maximum revenue from United States.